Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T Studies, Secures $35 Million Private Placement Equity Financing Priced at Market

HOUSTON - Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced positive interim data from its ongoing Phase 1/2 GoCAR-T clinical trials, including a confirmed partial response (PR) in the first cohort of mCRPC patients treated in the clinical trial for BPX-601.

Bellicum has also entered into an agreement for a $35 million private placement of equity securities with two biotechnology specialist investment funds. Proceeds from the financing will be used to support ongoing clinical development of BPX-601 and BPX-603.

'We are highly encouraged by the observation of anti-tumor activity of BPX-601 in the first mCRPC cohort, particularly in this heavily pre-treated patient population with limited therapeutic options,' said Rick Fair, President and Chief Executive Officer of Bellicum. 'The additional capital we raised through this private placement will support our ongoing clinical development of BPX-601 and BPX-603 to further pursue this early efficacy signal.'

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum's GoCAR-T product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'designed,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Bellicum's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing of interim results from Bellicum's clinical trials; Bellicum's plans for further clinical development of BPX-601 and BPX-603; the expected closing of the private placement and the expected use of proceeds from the offering and Bellicum's expected cash runway. Various factors may cause differences between Bellicum's expectations and actual results as discussed in greater detail under the heading 'Risk Factors' in Bellicum's filings with the Securities and Exchange Commission, including without limitation Bellicum's quarterly report on Form 10-Q for the three months ended September 30, 2021 and Bellicum's annual report on Form 10-K the year ended December 31, 2020. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update Bellicum's forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:

Robert H. Uhl

Tel: [phone]

Email: [e-mail]

(C) 2021 Electronic News Publishing, source ENP Newswire